Marlex Pharmaceuticals Inc.
New Castle, DE Doing business as Marlex Pharmaceuticals I
- UEI
- VSSNJEFMPLB3
- CAGE
- 1TAP7
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
-
- 236210 Industrial Building Construction
- 325411 Medicinal and Botanical Manufacturing
- 325611 Soap and Other Detergent Manufacturing
- 339113 Surgical Appliance and Supplies Manufacturing
- 423450 Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- 424490 Other Grocery and Related Products Merchant Wholesalers
- SAM.gov registration date
- Physical address
- 65 Lukens Dr, New Castle, DE 19720, USA
- Website
- marlexpharm.com
- Founded
- 1992
- Employees
- 1-10
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 51 Wholesale Trade – Nondurable Goods
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $109,115 |
| FY2025 | $34,134 |
| FY2024 | $39,691 |
| FY2023 | $31,231 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Logistics Agency | $109,115 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Chartwell RX LLC | Congers, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Exelan Pharmaceuticals Inc. | Boca Raton, FL | 325412 Pharmaceutical Preparation Manufacturing |
| Solco Healthcare US LLC | Franklin Township, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| FKA West-Ward Pharmaceuticals | Berkeley Heights, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Avkare LLC | Pulaski, TN | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Marlex Pharmaceuticals Inc., doing business as Marlex Pharmaceuticals I, manufactures and supplies generic pharmaceutical tablets to federal healthcare systems as a prime contractor under full-and-open procurement, with no set-aside usage across its federal footprint. A minority-owned, Subcontinent Asian American-owned small disadvantaged business headquartered in New Castle, Delaware, Marlex holds 472 prime awards (100% of recent activity) with combined potential value of $404.6 million, driven by high-volume delivery orders placed through established federal medical supply channels.
Marlex's customer concentration anchors heavily to the Veterans Health Administration and the Defense Logistics Agency. The top five funding entities account for 93% of recent awards by count and 99% by potential value. The Defense Logistics Agency Troop Support Medical dominates by award frequency with 391 delivery orders (combined potential value $89.5 million), while the Department of Veterans Affairs Veterans Integrated Service Network 12 leads by dollar value with 11 awards carrying $240.4 million in combined potential value. The VA National Acquisition Center contributes an additional $68.1 million across seven awards. Activity has grown sharply—from six awards in 2022 to 99 awards in 2026—reflecting sustained demand across federal beneficiary agencies. The recompete cliff shows only one award (combined potential value $100 thousand) completing in the next twenty-four months, indicating stable contract positioning with minimal near-term recompete exposure.
Marlex's product portfolio consists of prednisone, haloperidol, methocarbamol, loratadine, cetirizine HCl, thiamine, pyrazinamide, alendronate, ezetimibe, ropinirole HCl, and melatonin tablets in multiple dosages and formulations. Representative delivery orders include a $100,232.91 firm fixed-price order from the DLA Troop Support Medical (awarded June 2026) for generic pharmaceutical tablets supporting federal healthcare systems, and numerous $3 to $800+ individual line-item delivery orders for specific medications such as prednisone 20 mg tablets (100s), methocarbamol 500 mg tablets (500s), and hydroxyzine HCl 25 mg tablets across the DLA supply chain. Marlex also holds three major parent contract vehicles: an IDC (SPE2D020D0008) with 259 task orders valued at $286 thousand combined, an IDC (SPM2D012D0005) with 130 task orders valued at $64 thousand combined, and a GSA Federal Supply Schedule contract (V797P5688X, Pharmaceuticals and Drugs) awarded February 1, 2025, with a ceiling of $204.8 million through February 1, 2030. Three single-award indefinite-delivery contracts with the VA National Acquisition Center round out the vehicle portfolio: a $5.9 million melatonin tablets and capsules IDC (base year September 2026 through September 2027, with four one-year options), a $4.3 million alendronate tablets IDC (base year May 2026 through May 2027, with four one-year options), and a $14.1 million ezetimibe 10 mg tablets IDC (base year April 2024 through April 2025, with four one-year options). Place of performance spans nationwide, with supplies distributed through VA pharmaceutical prime vendor programs and the DLA supply chain to serve the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and Indian Health Service. Marlex operates exclusively as a prime contractor and does not subcontract work; all 472 awards reflect direct delivery of pharmaceutical products by the company.
Quick answers
Is Marlex Pharmaceuticals Inc. registered in SAM.gov?
Yes. Marlex Pharmaceuticals Inc.'s SAM.gov registration is active through September 3, 2027.
Which contract vehicles does Marlex Pharmaceuticals Inc. hold?
Marlex Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Marlex Pharmaceuticals Inc. received in federal contracts?
Federal contracts obligated $34,134 to Marlex Pharmaceuticals Inc. in fiscal year 2025 and $214,171 in fiscal years 2023 through 2027.
How does Marlex Pharmaceuticals Inc. rank among federal contractors?
Marlex Pharmaceuticals Inc. ranked #40 in NAICS 325411 in FY2025.
What is Marlex Pharmaceuticals Inc.'s most recent federal award?
Marlex Pharmaceuticals Inc.'s most recent federal contract award is Prednisone 20 MG tablet 100S (SPE2D326F298L), from Medical Supply Chain (DLA), on July 24, 2026.
On GovTribe
See Marlex Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors